UnknownPhase 2NCT01124539

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Arno Therapeutics
Principal Investigator: James J Vredneburgh, MD, MD
Duke University Medical Center - The Preston Robert Tisch Brain Tumor Center
Intervention: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)(drug)
Enrollment: 58 enrolled
Eligibility: 18 years · All sexes
Timeline: 2009 – 2015

Study locations (9)

Northwestern University - Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
University of Kentucky - Markey Cancer Center, Lexington, Kentucky, United States
North Shore - Long Island Jewish Hospital/Monter Cancer Center, Lake Success, New York, United States
Duke University Medical Center - The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
Derrick L Davis Forsyth Regional Cancer Center, Winston-Salem, North Carolina, United States
The Ohio State University - James Comprehensive Cancer Center, Columbus, Ohio, United States
University of Utah - Huntsman Cancer Center, Salt Lake City, Utah, United States
University of Calgary - Tom Baker Cancer Center, Calgary, Alberta, Canada
University of Alberta - Cross Cancer Institute, Edmonton, Alberta, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01124539 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials